Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51results about How to "Reduce proliferation" patented technology

Nanoparticle compound for inhibiting bone and soft tissue infection as well as preparation method and application thereof

The invention provides a nanoparticle compound for inhibiting bone and soft tissue infection as well as a preparation method and application thereof, and belongs to the technical field of medical biological materials. The nanoparticle compound is a gentiopicroside, sericin, hyaluronic acid and endolysin liposome nanoparticle, and a gentiopicroside, sericin, hyaluronic acid and endolysin co-delivery nano drug delivery system targeting the S100A4 site is designed based on the target S100A4 closely related to bone infection through Ai molecular docking and nano drug delivery technologies. The nanoparticle compound provided by the invention has better stability and bioavailability, and can be used for improving and relieving inflammatory response and increasing wound healing effect.
Owner:JIANGXI SCI & TECH NORMAL UNIV

Application of OLFM3 as neuroblastoma drug target

The invention belongs to the field of gene diagnosis and treatment, and particularly relates to application of OLFM3 as a neuroblastoma drug target. The invention provides application of a reagent for inhibiting OLFM3 gene expression in preparation of a medicine for treating MYCN amplified neuroblastoma. The invention discovers that the OLFM3 has high specific expression in MYCN amplified neuroblastoma cells, and has low expression in MYCN non-amplified neuroblastoma cells; in MYCN amplification of neuroblastoma cells, the OLFM3 is knocked down to weaken the proliferation and clone formation ability of the neuroblastoma cells. The OLFM3 promotes malignant proliferation of MYCN amplified neuroblastoma cells, is a new driving gene for malignant proliferation of MYCN amplified neuroblastoma cells, and is prompted to be a new target for treating MYCN amplified neuroblastoma.
Owner:BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Application of umbilical cord mesenchymal stem cells and monoclonal antibody in combined treatment of cancer

The invention belongs to the technical field of biological medicines, and particularly relates to application of umbilical cord mesenchymal stem cells and monoclonal antibodies in combined treatment of cancers. The monoclonal antibody is a monoclonal antibody specifically aiming at human PAFAH1B3 protein, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 2. The PAFAH1B3 protein monoclonal antibody can significantly inhibit the proliferation capacity of pancreatic cancer cells, and after the umbilical cord mesenchymal stem cells and the PAFAH1B3 protein monoclonal antibody are combined for use, the inhibition effect on the proliferation capacity of the pancreatic cancer cells is better, and the umbilical cord mesenchymal stem cells can be used for preparing anti-cancer drugs and have good application prospects.
Owner:HUASHENG BIOLOGICAL (HENAN) CO LTD

Breeding method for improving immunity of fishes

The invention provides a culture method for improving immunity of fishes. The culture method comprises the following steps: S1, selection of culture points; S2, specification and layout of net cages; S3, selection and throwing of fish fries; according to the fry disinfection method disclosed by the invention, the fry are soaked and disinfected by using a compound disinfectant prepared from povidone iodine, polysorbate, citric acid and vitamin C in a specific proportion, so that pathogenic microorganisms on the surfaces and gill parts of fish bodies are effectively killed. According to the breeding management, the immunity of the fish body is comprehensively enhanced by feeding the fish with an immune conditioner composed of campesterol palmitate, immunomodulatory peptide, beta-glucan and astaxanthin in a specific proportion. According to the bottom mud management, the content of harmful substances is reduced by putting a bottom mud modifier composed of sodium molybdate, nitrifying bacteria, photosynthetic bacteria, tetrandrine and sodium alginate in a specific proportion, growth of pathogenic bacteria is inhibited, nutrient substance circulation is promoted, the water quality environment is optimized, and healthy growth of fry is promoted.
Owner:SANYA SHUANGFANSHI FISHERY TECH CO LTD

Application of piRNA as target spot in preparation of medicine for treating lung cancer or lung injury caused by tobacco exposure

The invention relates to application of piRNA as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and belongs to the technical field of biomedicine. The invention provides application of piR-2850767 and / or piR-157618 as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and particularly relates to application of an expression inhibitor of piR-2850767 and / or an overexpression reagent of piR-157618 in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure. The inhibitor and the overexpression preparation can cause growth inhibition of lung cancer representative cells A549 and cause apoptosis of the lung cancer representative cells A549, and can recover cell cycle arrest, cell apoptosis, cell proliferation and motor ability decline of lung epithelial cells caused by tobacco exposure as a preventive drug for lung injury caused by tobacco exposure.
Owner:HUAZHONG UNIV OF SCI & TECH

Genetically engineered exosome as well as slow release method and application thereof

The invention discloses a gene engineering exosome and a slow release method and application thereof, the gene engineering exosome is derived from human adipose-derived stem cells, si-tgfbr2 is loaded in the gene engineering exosome, the si-tgfbr2 is specific siRNA aiming at a Tgfbr2 gene, and the gene engineering exosome can regulate and control proliferation of VSMCs, inhibit transformation of the VSMCs from a contraction phenotype to a synthetic phenotype when the VSMCs are stimulated, and inhibit the growth of the VSMCs. According to the present invention, the gene engineering exosome can be used to maintain the normal structure and the function of the blood vessel, and the sustained release effect of the content in the gene engineering exosome can be achieved by wrapping the gene engineering exosome in the PHA biodegradable material, such that the local treatment concentration can be easily stabilized, the drug administration frequency can be easily reduced, the lasting time of the treatment effect can be easily prolonged, and the treatment gene can be effectively delivered to the target cell; the treatment effect is improved; when being used for modifying a small-caliber artificial blood vessel, the small-caliber artificial blood vessel can be improved in biocompatibility and functionality, and can be prevented from being implanted into the blood vessel for remodeling unbenign hyperplasia stenosis; the invention not only provides a new thought and method for the treatment of vascular diseases, but also has important clinical application value and popularization prospect.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Preparation method of oil control agent with biological activity as well as product and application of oil control agent

The invention relates to a preparation method of an oil control agent with biological activity as well as a product and application of the oil control agent. The preparation method comprises the following steps: (1) mixing glucose, diammonium citrate, a soybean extracting solution, kaolin and water to obtain a mixed solution; (2) inoculating lactobacillus acidophilus into the mixed solution for fermentation to obtain a first fermented product; (3) inoculating saccharomycetes into the first fermentation product for fermentation, and feeding zinc gluconate in the fermentation process; (4) after fermentation is finished, adding biological enzyme for enzymolysis treatment to obtain enzymatic hydrolysate; (5) carrying out solid-liquid separation on the enzymatic hydrolysate, and respectively collecting filtrate and filter residues; (6) drying the filter residue, and crushing to obtain active kaolin; drying the filtrate to obtain spray-dried powder; and (7) combining the active kaolin and the spray-dried powder through a fluidized bed to obtain the oil control agent with biological activity. The oil control agent prepared by the method provided by the invention has a moisturizing effect while controlling oil, and has a wide application prospect and a huge market value.
Owner:GUANGDONG LIYAN BIOTECHNOLOGY CO LTD

Application of ANGPTL4 gene in preparation of medicine for treating pulmonary arterial hypertension

The invention relates to the technical field of biological medicine. The invention provides an application of an ANGPTL4 gene in preparation of a medicine for treating pulmonary arterial hypertension, and a reagent capable of knocking out or silencing the ANGPTL4 gene. Hypoxic pulmonary hypertension can be improved and pulmonary artery remodeling can be relieved by inhibiting expression of the ANGPTL4 gene; oxidative damage and proliferation of pulmonary artery smooth muscle cells under pulmonary hypertension are reduced; and pulmonary artery smooth muscle cell mitochondrial dysfunction can be treated. A new direction is provided for improving the treatment effect and the prognosis effect of the hypoxic pulmonary hypertension patient.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Application of asparaginase in preparation of medicine for treating pancreatic cancer

The invention belongs to the technical field of biological medicines, and particularly relates to application of asparaginase in preparation of a medicine for treating pancreatic cancer. The asparaginase and the gemcitabine are combined for treating pancreatic cancer, and results show that the combination of the two medicines can promote apoptosis of pancreatic cancer cells, reduce proliferation and reduce activation of pancreatic stellate cells, so that an important scientific basis is provided for improving gemcitabine drug resistance, and meanwhile, a new application is provided for the asparaginase.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Use of nutritional composition for assisting in improving memory ability

The invention belongs to the field of food, and particularly relates to application of a nutritional composition to auxiliary improvement of memory ability. The invention provides application of a nutritional composition in preparation of food which is taken by a mother to assist in improving memory ability of offspring. The nutritional composition comprises the following necessary components: active folic acid substances and N-acetylneuraminic acid, furthermore, in the nutritional composition, the mass ratio of the active folic acid substances to the N-acetylneuraminic acid is (0.0005 to 0.007) to (1 to 5); the mother comprises a mother in a gestation period and / or a mother in a lactation period, and the filial generation comprises a filial generation in a fetal period and / or a filial generation in an infant period and an optional filial generation in a child period. A large number of studies find that the composition of active folic acid substances and N-acetylneuraminic acid is supplemented to the pregnant mothers and / or the lactation mothers, and the positive effect can be achieved on the memory ability of the offspring.
Owner:FEIHE (AR HORQIN BANNER) DAIRY CO LTD +1

Application of samidocardone in preparation of medicine for treating pulmonary fibrosis

The invention discloses an application of samidocardone in preparation of a medicine for treating pulmonary fibrosis. According to the application disclosed by the invention, the condition that the samidojun can inhibit the activity of the pulmonary fibrosis cells and reduce proliferation by inducing the ferroptosis of the pulmonary fibrosis cells is proposed and verified for the first time, and meanwhile, the expression of fibrosis-related proteins is reduced, so that the progress of the pulmonary fibrosis is effectively relieved, and a new direction is provided for treating the pulmonary fibrosis.
Owner:NANTONG UNIV

A double-coated nanoemulsion of clove essential oil and its preparation method and use

The present invention belongs to the technical field of biological preservatives, and specifically relates to a double-coated nanoemulsion of clove essential oil, which comprises clove essential oil, ε-polylysine, whey protein, lecithin, and corn starch. The present invention also provides a preparation method of the nanoemulsion and its use as a donkey meat preservative. The double-coated nanoemulsion of clove essential oil of the present invention not only retains the excellent properties of the original nanoemulsion, but also slows down the increase of pH value, the proliferation of microorganisms, and the oxidation of lipids and proteins to a certain extent, and greatly prolongs the shelf life.
Owner:LIAOCHENG UNIV

Preparation method and application of psoriasis repair factor preparation

The invention discloses a preparation method and application of a psoriasis repair factor preparation, relates to the field of preparations for treating psoriasis, and aims to solve the problems of poor treatment effect and obvious inflammatory response in the existing method for treating psoriasis by directly using MSC (mesenchymal stem cell) transplantation. The method comprises the following steps: 1, separating Wharton's jelly from umbilical cord tissues to obtain UMSCs; purifying and culturing, and treating the cells by adopting intense pulsed light; 2, culturing the UMSCs to the third generation, collecting cell culture supernate, and extracting exosomes; and 3, diluting the exosome with normal saline to obtain the psoriasis repair factor preparation. The method can promote secretion of MSCs exosomes, increase the content of psoriasis repair factors in the exosomes, inhibit Glut 1 expression, inhibit keratinocytes from secreting TSLP and promote Treg cell proliferation and differentiation. The traditional Chinese medicine composition is used for improving the treatment effect of psoriasis.
Owner:TIAN QING STEM CELL CO LTD

Preparation method and application of anti-breast cancer implantation stent based on paclitaxel / polylactic acid composite material

PendingCN118987376Areduce proliferationavoid allergic reactionsSurgeryOncologyCancer research
The invention discloses a preparation method and application of an anti-breast cancer implantation stent based on a paclitaxel / polylactic acid composite material in the technical field of medicine preparation, paclitaxel and polylactic acid powder are uniformly mixed and extruded into a wire rod through a hot melting extrusion technology, then the obtained wire rod is printed and formed through a fused deposition technology, and a PTX / PLA stent is obtained. The reticular porous scaffold prepared by the invention can slowly release paclitaxel at a focus, avoids anaphylactic reaction caused by use of a solvent, can effectively reduce proliferation of breast cancer cells, has small toxic and side effects, and is suitable for application in breast cancer treatment.
Owner:YANGZHOU UNIV

Application and method of KRT17 gene in retarding proliferation of pulmonary artery smooth muscle cells

The invention belongs to the field of diagnosis and molecular biology, and particularly relates to application and a method of a KRT17 gene in slowing down proliferation of pulmonary artery smooth muscle cells. According to the invention, high expression of KRT17 in PAH and hypoxia-induced PASMCs is found and proved, and proliferation of pulmonary artery smooth muscle cells can be slowed down by knocking out KRT17, so that a foundation is provided for subsequent development of KRT17 genes in cardiovascular diseases.
Owner:LIANYUNGANG FIRST PEOPLES HOSPITAL

Application of NOTCH3 as target in preparation of pharmaceutical composition for treating bladder cancer

The invention belongs to the technical field of medicines, and particularly relates to application of NOTCH3 serving as a target spot to preparation of a pharmaceutical composition for treating bladder cancer. The invention relates to a targeted inhibitor of NOTCH3, which is shRNA (short hairpin ribonucleic acid). Experimental results show that NOTCH3 is a key oncogene of bladder cancer and can be used as a therapeutic target of bladder cancer, and an inhibitor of NOTCH3 can be used for preparing a pharmaceutical composition for treating bladder cancer.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV

Application of compound in inhibition of Aurora and JAK kinase family activity and treatment of several tumors

The invention relates to the technical field of chemical medicines, in particular to application of a compound 2-(4-methanoyl) anilino-4-(1H-indole-4-oxy)-5-trifluoromethylpyrimidine in inhibition of the activity of Aurora and JAK kinase families and in treatment of several tumors. On the basis of the research of 2-(4-methanoyl) anilino-4-amino-5-trifluoromethylpyrimidine derivative and application (patent application number: 202110571344.8) in the early stage, the compound is found to be capable of inhibiting the activity of FAK kinase and effectively inhibiting the family activity of Aurora and JAK kinase, and the inhibition effects are respectively 100 times and 5 times or more superior to those of the FAK kinase, so that the compound can be used for preparing a novel compound for inhibiting the activity of the FAK kinase. The compound can be used as a dual-effect anti-tumor inhibitor and can reduce proliferation of breast cancer, lung cancer, leukemia, thyroid cancer, prostate cancer, glioma, ovarian cancer and lymphoma cells, the activity is not observed in other FAK kinase inhibitors (such as Defactinib), and the compound can be used as a dual-effect anti-tumor inhibitor. The compound is applied to preparation of medicines for treating breast cancer, lung cancer, leukemia, thyroid cancer, prostate cancer, glioma, ovarian cancer, lymphoma and idiopathic pulmonary fibrosis.
Owner:GUIZHOU MEDICAL UNIV

Use of NLN neurolysin in the preparation of drugs for treating lung cancer

The present invention provides a use of NLN neurolysin in preparing a drug for preventing and treating lung cancer, and the present invention belongs to the field of medical science. It is first found that the level of NLN neurolysin in lung cancer tissue of lung cancer patients is significantly higher than that in adjacent cancer tissue. The present invention verifies that knocking out the NLN neurolysin gene can effectively prevent and treat lung cancer through gene knockout, and the present invention provides a target and treatment strategy for clinical treatment of lung cancer.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Mediating METTL3 variable splicing oligonucleotide and application thereof in preparation of medicine for treating hepatocellular carcinoma

The invention discloses oligonucleotide mediating METTL3 variable splicing and application of the oligonucleotide in preparation of a medicine for treating hepatocellular carcinoma. The sequence of the oligonucleotide is any sequence as shown in SEQ ID No.1-7. According to the invention, the expression of the METTL3 splicing isomer is regulated in a targeted manner by using a specific ASO drug, the expression level of the METTL3-A splicing isomer for promoting cancer is reduced, and the expression level of the METTL3-D splicing isomer for inhibiting cancer is increased. The proliferation and clone formation capabilities of hepatoma cells with increased expression of METTL3-D splicing isomers are greatly reduced, and meanwhile, the invasion capability is also remarkably weakened. The expression of the METTL3-D splicing isomer is crucial to the inhibition of liver cancer cells. METTL3 variable splicing regulation provides a new target for clinical treatment of liver cancer, and has a remarkable clinical application prospect. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the expression of the METTL3-A splicing isomer capable of promoting the cancer in liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the proliferation and the clone formation capability of liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 provided by the invention can be used for efficiently inhibiting the invasion ability of liver cancer cells.
Owner:ANHUI MEDICAL UNIV

Preparation and application of bio-based active preservative film based on synergistic utilization of rice bran multi-components

PendingCN122668417ARealize synergyImprove use value
This invention discloses the preparation and application of a bio-based active preservation film based on the synergistic utilization of multiple components of rice bran. Using defatted rice bran as the raw material, the invention employs bacterial cellulose obtained from the fermentation of defatted rice bran hydrolysate as the structural framework of the membrane matrix. Rice bran protein from the hydrolysis residue of defatted rice bran is prepared into nanoparticles, and a Pickering emulsion is formed by stabilizing thyme essential oil with these nanoparticles. Further, the defatted rice bran-based bacterial cellulose membrane is impregnated and modified with polyvinyl alcohol and glycerol. Then, the rice bran protein-stabilized thyme essential oil Pickering emulsion is coated onto the surface of the modified membrane matrix to obtain a bio-based active preservation film. The resulting preservation film can be used for the preservation and packaging of chilled meat, and can delay microbial proliferation, lipid oxidation, protein spoilage, and color deterioration during the storage of chilled meat.
Owner:NANJING AGRICULTURAL UNIVERSITY

A traditional Chinese medicine fermented longan ginseng peptide probiotic powder for treating tumors

The present invention belongs to the field of preparation of longan ginseng peptide probiotic powder, and particularly relates to a traditional Chinese medicine fermented longan ginseng peptide probiotic powder for treating tumors. Ginseng and American ginseng are crushed and powdered, vacuum concentrated to make ginseng peptide concentrate, and mixed with dried longan, artemisia annua, ashwagandha, knotweed, tripterygium wilfordii, cordyceps sinensis, and composite probiotic agents in a fermenter for full fermentation. The effective ingredient content is high and is conducive to absorption, while clearing away heat and promoting body fluid without toxic side effects; finally, the traditional Chinese medicine fermented longan ginseng peptide probiotic powder prepared by vacuum freeze drying has minimal biological activity damage, completely retains the active ingredients for treating tumors, and is convenient for long-term storage. After liver cancer mice take it, the tumor weight and volume are effectively suppressed, the liver function is less damaged, and the immune function of mice is protected, and the macrophage phagocytosis rate of mice reaches 79.6%.
Owner:JILIN TIANSANQI PHARM CO LTD

Application of Ero1alpha as pulmonary arterial hypertension biomarker and therapeutic target

The invention discloses an application of Ero1alpha as a pulmonary arterial hypertension biomarker and a therapeutic target. The embodiment of the invention shows that the Ero1alpha is highly expressed in low-oxygen pulmonary artery smooth muscle cells and pulmonary artery high-pressure lung tissues, the proliferation and migration level of the pulmonary artery smooth muscle cells is reduced by knocking down the Ero1alpha, and the reverse effect is caused by overexpression of the Ero1alpha; pulmonary arterial hypertension caused by hypoxia and MCT can be remarkably relieved by knocking down expression of Ero1alpha at an animal level. The invention reveals that the Ero1alpha can be used as a new target for diagnosing and treating the pulmonary arterial hypertension, a treatment strategy aiming at the Ero1alpha can be developed, and a more effective treatment method is provided for patients with the pulmonary arterial hypertension. As a key biomarker and a therapeutic target, Ero1alpha has an important application prospect in diagnosis and treatment of pulmonary arterial hypertension.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV

Pharmaceutical composition, for preventing or treating fibrotic diseases, comprising progranulin protein or active fragments thereof as active ingredient

The present invention relates to a pharmaceutical composition and the like, for preventing or treating pulmonary or airway fibrosis, comprising a progranulin (PGRN) protein or active fragments thereof as an active ingredient. The present invention is accomplished by confirming that progranulin and active fragments thereof can effectively inhibit pulmonary and airway inflammation and fibrosis. Particularly, the present inventors injected a progranulin and active fragments (PGRN-FBAC, PGRN-BACD and PGRN-CDE) thereof to a pulmonary fibrosis animal model and, as a result, confirmed reduced infiltration of inflammatory cells into the pulmonary and airway tissues and reduced fibroblast proliferation and collagen production as well as relief in inflammation-induced tissue damage. Further, the inventors induced an inflammatory response from an epithelial cell line and pulmonary fibroblasts and treated same with progranulin and active fragments thereof and, as a result, confirmed reduced levels and activities of fibronectin, p-NFκB, COL1A1, F-actin and the like which are fibrosis markers. Since said results exhibit effects of the progranulin protein and active fragments thereof in relieving pulmonary and airway inflammation and fibrosis, the progranulin protein and active fragments thereof according to the present invention are expected to be utilized as therapeutic means for various diseases induced by pulmonary and airway fibrosis.
Owner:THE ASAN FOUND +1

Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof

Provided in the present invention is a pharmaceutical composition comprising hydroxyprogesterone caproate and an additional therapeutic agent for treating tumors, wherein the additional therapeutic agent is preferably a monoclonal antibody against PD-1 or PD-L1. Further provided in the present invention are a method for increasing the number of tumor infiltrating lymphocytes (TIL) as required and a method for treating cancers in a subject in need thereof, which comprises providing the hydroxyprogesterone caproate to the subject.
Owner:SHENZHEN EVERGREEN THERAPEUTICS CO LTD

Application of PLA2G4F protein as therapeutic target in preparation of medicine for treating triple negative breast cancer

The invention discloses an application of PLA2G4F protein as a therapeutic target in preparation of a medicine for treating triple negative breast cancer, and discloses that three siRNAs selectively inhibit PLA2G4F on transcription and translation levels, and inhibition of PLA2G4F can significantly reduce cell proliferation and increase apoptosis and also damage TNBC cancer cells; specifically, inhibition of PLA2G4F causes obvious reduction of lipid formation, and also inhibition of expression of lipid metabolism genes in TNBC cells. The invention provides a new drug treatment target for treating the triple negative breast cancer, and has important scientific significance in the aspects of subsequent drug research and development, clinical treatment and the like.
Owner:JIANGSU CANCER HOSPITAL

Skin bacteriostatic liquid containing plant extract and preparation method thereof

PendingCN122681759AThe inhibitory effect hasEnhanced inhibitory effect
The application relates to the technical field of skin bacteriostatic liquid, and discloses a skin bacteriostatic liquid containing plant extracts and a preparation method thereof, which comprises the following raw materials in parts by mass: composite plant extracts containing nanocrystalline particles 15-20 parts, glycerol 3-4 parts, sodium hyaluronate 0.1-0.2 parts and purified water 75-85 parts. The composite plant extracts containing nanocrystalline particles, glycerol, sodium hyaluronate and purified water are mixed to obtain the skin bacteriostatic liquid, which has the advantages of strong bacteriostasis, long-acting bacteriostasis, mildness and no irritation, and can repair the skin barrier, realize long-acting skin bacteriostasis, reduce the repeated occurrence of skin inflammation, and relieve inflammatory skin aging.
Owner:WUHAN KONIME BOLOGICAL TECH CO LTD

Application of miR-196b-5p as colorectal cancer diagnosis or treatment marker

The invention discloses application of microRNA (Ribonucleic Acid) as a diagnostic marker in an advanced colorectal cancer drug resistance diagnostic kit and application of microRNA in preparation of drugs for treating advanced colorectal cancer. The invention discovers that miR-196b-5p is highly expressed in a cetuximab-sensitive intestinal cancer cell line, and the expression quantity of miR-196b-5p in a drug-resistant intestinal cancer cell line is generally low. The miR-196b-5p is subjected to an overexpression or knockout experiment, which proves that the miR-196b-5p can effectively influence the sensitivity of intestinal cancer cells to cetuximab. The miR-196b-5p is expected to become a novel biomarker for early prediction and screening of drug resistance of colorectal cancer patients using cetuximab, and assists in dynamic monitoring of curative effect and overcoming of drug resistance.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

A method for degrading toxic and harmful substances in channel catfish breeding pond sediment and inhibiting the proliferation of pathogenic bacteria in the sediment

The present invention discloses a method for degrading toxic and harmful substances in the bottom mud of channel catfish breeding ponds and inhibiting the proliferation of pathogenic bacteria in the bottom mud. It belongs to the field of breeding technology. The whole breeding process adopts the technology of precise feeding of biological fermented feed and the technology of replacing antibiotics with inulin, which complement each other. The core is to build a "double-effect" relationship of "probiotics-prebiotics". After use, it can significantly degrade organic matter in the bottom mud, greatly reduce the production of toxic and harmful products such as ammonia nitrogen and the proliferation of pathogenic bacteria such as Proteobacteria. When the above-mentioned technologies are used alone, the effects are not as significant as when they are used simultaneously. At the same time, after tracking for two consecutive breeding cycles, it was found that the output and specifications of channel catfish were significantly improved, and the breeding benefits of fishermen increased significantly.
Owner:FRESHWATER FISHERIES RES INSITUTE OF JIANGSUPROVINCE

Application of KIF4B as biomarker for predicting prognosis of lung cancer patient

The invention discloses an application of KIF4B as a biomarker for predicting prognosis of a lung cancer patient, relates to the technical field of biomedicine, and particularly relates to an application of KIF4B as a biomarker in preparation of NSCLC for prognosis and treatment. The research finds that the KIF4B gene is obviously and highly expressed in the NSCLC, and the expression of the KIF4B gene has obvious correlation with the prognosis, pathological grading, TN staging, invasion and infiltration and tumor size of the NSCLC; fluorescence multiple immunohistochemistry shows that the expression of the gene is in significant positive correlation with the expression of A549 and NCI-H1299 human NSCLC cell lines; the expression of the KIF4B gene is regulated in a targeted manner by using specific shRNA, and the expression level of the KIF4B gene is reduced, so that the proliferation and migration capabilities of NSCLC cells are greatly reduced, which indicates that the expression of the KIF4B gene is crucial to the NSCLC cells. The invention proves that the expression of the KIF4B gene is closely related to NSCLC cells, provides a new target source for prevention, diagnosis, detection and research of NSCLC, and provides a new drug preparation idea and clinical application prospect for NSCLC treatment.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Application of siRNA for targeted inhibition of rabies virus G gene and / or L gene in preparation of drugs for inhibiting rabies

The invention discloses application of siRNA for targeted inhibition of rabies virus G gene and / or L gene in preparation of drugs for inhibiting rabies. SiRNA-G for targeted inhibition of a rabies virus G gene and siRNA-L for targeted inhibition of a rabies virus L gene are provided on the basis, the nucleotide sequence of a sense strand of the siRNA-G is as shown in SEQ ID NO: 1, and the nucleotide sequence of an antisense strand of the siRNA-G is as shown in SEQ ID NO: 2; the nucleotide sequence of the positive-sense strand of the siRNA-L is as shown in SEQ ID NO: 3, and the nucleotide sequence of the antisense strand of the siRNA-L is as shown in SEQ ID NO: 4. The siRNA-G and / or siRNA-L can effectively inhibit the expression of the G gene and the L gene of the rabies virus and reduce the proliferation of the rabies virus, and can be used as an effective small nucleic acid drug in the development process of anti-rabies virus drugs.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY